# Kisspeptin: The Upstream Switch of the Reproductive Hormone Axis > Kisspeptin activates KISS1R on GnRH neurons, driving the entire reproductive hormone cascade. Published findings on mechanism, isoforms, IVF trials, and neuroendocrine research — indexed and cited. ## What is kisspeptin? Kisspeptin is a neuropeptide family encoded by the KISS1 gene. The primary precursor protein — 145 amino acids — is cleaved to produce the 54-amino-acid isoform (KP-54) and shorter fragments including KP-14, KP-13, and KP-10. All isoforms share a conserved C-terminal RF-amide motif (Arg-Phe-NH2) required for receptor binding. [1] The receptor: KISS1R, formerly designated GPR54. It is a Gq/11-coupled G-protein-coupled receptor expressed on hypothalamic GnRH neurons. When kisspeptin binds KISS1R, it activates phospholipase C, triggering IP3-mediated calcium release that depolarizes the GnRH neuron by approximately 6 mV, sustaining elevated firing for about 21 minutes. [4] GnRH neurons, once activated, release gonadotropin-releasing hormone into the hypothalamic-pituitary portal system. The pituitary responds with LH and FSH secretion; the gonads respond with testosterone and estradiol production. Kisspeptin initiates this entire cascade. Kisspeptin is not FDA-approved for any clinical indication as of 2025. It is the subject of an active and growing research literature, which is what this site documents. [22] ## What is kisspeptin used for in research? Five clinical research arms have generated published peer-reviewed data on kisspeptin: **Puberty and reproductive axis genetics.** Loss-of-function KISS1R mutations cause idiopathic hypogonadotropic hypogonadism and absent puberty onset (Seminara 2003, NEJM). [1] Gain-of-function KISS1R mutations cause central precocious puberty (Teles 2008, NEJM). [2] Inactivating KISS1 mutations cause hypogonadotropic hypogonadism and pubertal failure (Topaloglu 2012, NEJM). [3] **Hypothalamic amenorrhea and fertility restoration.** Kisspeptin-54 infusion restored pulsatile LH secretion in women with hypothalamic amenorrhea — mean LH pulse frequency rose approximately 3-fold, pulse secretory mass approximately 6-fold versus vehicle (Jayasena 2014, JCEM). [7] **IVF oocyte maturation triggering.** Kisspeptin-54 at 9.6 nmol/kg SC triggered oocyte maturation in 95% of high-OHSS-risk IVF patients with zero OHSS cases at any tested dose and a live birth rate of 62% at the optimal dose (Abbara 2015, JCEM). [9] **Hypogonadism and testosterone.** IV kisspeptin-10 (1.5 µg/kg/h infusion) raised mean LH from 5.2 to 14.1 IU/L and elevated serum testosterone in healthy men (George 2011, JCEM). [5] **Psychosexual disorders.** fMRI showed kisspeptin-54 modulated brain activity across the sexual-response network (Cohen d = 0.81) and increased penile tumescence by 56% above placebo in men with hypoactive sexual desire disorder (Mills 2023, JAMA Network Open). [13] ## Kisspeptin Benefits Reported in Research **LH and testosterone elevation.** IV kisspeptin-10 produced dose-dependent LH rises within minutes of bolus administration. [5] **Fertility-axis restoration.** In women with hypothalamic amenorrhea, kisspeptin-54 infusion temporarily restored LH pulsatility. [7] **IVF safety profile.** Kisspeptin-54 triggered oocyte maturation without OHSS risk in high-responder patients. Zero moderate, severe, or critical OHSS cases at any tested dose. [9] **Safety record.** No serious adverse events across more than 1,000 kisspeptin administrations (Velmurugan 2025). [22] ## Does kisspeptin raise testosterone? In published research in men, yes — via an indirect upstream mechanism. Kisspeptin-10 IV infusion (1.5 µg/kg/h) raised mean LH from 5.2 to 14.1 IU/L and elevated serum testosterone (George 2011, JCEM). [5] In men with type 2 diabetes and mild biochemical hypogonadism, 0.3 µg/kg IV bolus normalized LH and testosterone over 11 hours (George 2013, Clinical Endocrinology). [6] ## References [1] Seminara SB, et al. The GPR54 Gene as a Regulator of Puberty. New England Journal of Medicine. 2003;349:1614-1627. https://www.nejm.org/doi/full/10.1056/NEJMoa035322 [2] Teles MG, et al. A GPR54-Activating Mutation in a Patient with Central Precocious Puberty. NEJM. 2008;358(7):709-715. https://pubmed.ncbi.nlm.nih.gov/18272894/ [3] Topaloglu AK, et al. Inactivating KISS1 Mutation and Hypogonadotropic Hypogonadism. NEJM. 2012;366(7):629-635. https://pubmed.ncbi.nlm.nih.gov/22335740/ [4] Liu X, Lee K, Herbison AE. Kisspeptin excites GnRH neurons through a PLC/calcium-dependent pathway. Endocrinology. 2008. https://pubmed.ncbi.nlm.nih.gov/18483150/ [5] George JT, et al. Kisspeptin-10 is a potent stimulator of LH in men. JCEM. 2011. https://pubmed.ncbi.nlm.nih.gov/21632807/ [6] George JT, et al. Kisspeptin-10 stimulates LH and testosterone in men with type 2 diabetes. Clinical Endocrinology. 2013;79(1):100-104. [7] Jayasena CN, et al. Increasing LH Pulsatility in Women With Hypothalamic Amenorrhoea Using IV Infusion of Kisspeptin-54. JCEM. 2014. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207927/ [9] Abbara A, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of OHSS During IVF. JCEM. 2015;100(9):3322-3331. https://pubmed.ncbi.nlm.nih.gov/26192876/ [13] Mills EG, et al. Effects of Kisspeptin on Sexual Brain Processing in Men With HSDD. JAMA Network Open. 2023. https://pubmed.ncbi.nlm.nih.gov/36735255/ [14] Thurston L, et al. Effects of Kisspeptin Administration in Women With HSDD. JAMA Network Open. 2022. https://pubmed.ncbi.nlm.nih.gov/36287566/ [21] Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety. JCEM. 2025. https://pubmed.ncbi.nlm.nih.gov/40036336/ [22] Velmurugan H, et al. Kisspeptin and its Current Clinical Status. Current Medicinal Chemistry. 2025;32(7):1313-1322. https://pubmed.ncbi.nlm.nih.gov/38265397/ --- The KISS1 record — mechanism, isoforms, and clinical trials — indexed here. Not a clinic, not a vendor.